Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Silvia MessinaClaudio SolaroIsabella RighiniRoberto BergamaschiSimona BonavitaRoberto Bruno BossioVincenzo Brescia MorraGianfranco CostantinoPaola CavallaDiego CentonzeGiancarlo ComiSalvatore CottoneMaura Chiara DanniAda FranciaAlberto GajofattoClaudio GasperiniMauro ZaffaroniLoredana PetrucciElisabetta SignorielloGiorgia Teresa ManiscalcoGabriella SpinicciManuela MattaMassimiliano MirabellaGraziella PedàLetizia CastelliMarco RovarisEdoardo SessaDaniele SpitaleriDamiano PaolicelliAlfredo GranataMario ZappiaFrancesco Pattinull null

Published in: PloS one (2017)

These data show that the first 6 weeks are useful in identifying those patients in which Sativex could be effective, thus avoiding the cost of longer term evaluation.

Keyphrases

end stage renal disease
multiple sclerosis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
machine learning
patient reported
white matter
preterm birth